Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.
Sacral neuromodulation (SNM) is still considered the gold standard neuromodulation option for refractory overactive bladder ...
The FDA approved remibrutinib (Rhapsido; Novartis) today, October 7, 2026, as the first treatment for adults with symptomatic ...
Risk assessment in mantle cell lymphoma (MCL) is evolving beyond traditional clinical scores, as genomic and dynamic ...
Bilbrey’s Tennessee Oncology colleage Johnetta Blakely, MD, MS, MMHC, who is also chief medical officer for COA, has ...
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
AJMC: Despite ATTR-CM being a progressive disease, 74% of patients reported no change in perception. Is that reassuring from ...
"We believe retatrutide is a biologic application," Eli Lilly’s CEO Dave Ricks, MBA, told analysts on the company's second-quarter earnings call in August. The outcome will shape how long retatrutide ...
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most. Invivyd's investigational monoclonal antibody VYD2311 showed superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results